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Abstract 
Gangliosides are sialic acid-containing glycosphingolipids expressed on all vertebrate 
cells. They are primarily positioned in the plasma membrane, with the ceramide part 
anchored in the membrane and the glycan part exposed on the surface of the cell. These 
lipids have highly diverse structures, in particular with respect to their carbohydrate 
chains, with N-acetylneuraminic acid (NeuAc) and N-glycolylneuraminic acid (NeuGc) 
being the two most common sialic acid residues in mammalian cells. Generally, human 
healthy tissue is considered nearly deficient in NeuGc, but since this molecule is present 
in tumors and in human fetal tissues, it was earlier classified as an onco-fetal antigen. 
Gangliosides perform important functions through carbohydrate-specific interactions with 
proteins, for example as receptors in cell-cell recognition, which can be exploited by 
viruses and other pathogens, and also by regulating signaling proteins through lateral 
interaction in the membrane. Through both mechanisms, tumor-associated gangliosides 
may affect malignant progression, which makes them attractive targets for cancer 
immunotherapies.  
 
In this thesis, the ganglioside NeuGc GM3 is the focus of attention. Different approaches 
have been used in order to reveal both its importance in cancer progression but also its 
potential for cancer immunotherapy.  In particular, we investigated the effect of hypoxia 
on tumor cells, since hypoxic conditions are known to induce a change in carbohydrate 
determinants correlating with a more aggressive and therapy-resistant phenotype. We 
studied alterations in protein expression as a response to hypoxia, using stable isotope 
labeling with amino acids in cell culture (SILAC) in combination with LC-MS/MS. The 
results obtained from the quantitative proteome analysis uncovered proteins important in 
hypoxia-induced cancer progression, representing potentially interesting targets in future 
therapies. The same method (SILAC) was used in order to study the cell death killing 
mechanism employed by a promising monoclonal antibody (14F7) that specifically 
targets NeuGc GM3. The identified proteins advance our understanding of this novel 
mechanism of cell killing. In addition, we studied the molecular interaction between the 
antibody 14F7 and its antigen NeuGc GM3 or its anti-idiotypic antibody using a 
 
combination of mass spectrometry-based methods and surface plasmon resonance 
(SPR).   
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1. Introduction 
1.1 Gangliosides 
Few lipid species included in biological membranes have received as much attention as 
glycosphingolipids (GSLs), and especially gangliosides, sialic-acid containing GSLs. 
They were discovered by Ernst Klenk in the 1940’s and later named by Svennerholm in 
1956 according to the number of sialic acid and chromatographic mobility (Svennerholm 
1956). These molecules are complex, diverse and consist of a ceramide anchor linked to 
a hydrophilic sugar part, characterized by the presence of one or more sialic acid 
residues. As an example, the GM3 ganglioside, which is abundant in almost all healthy 
tissues, is shown in Figure 1. The large structural variability is related to developmental 
stage and cell type, and more than hundreds of gangliosides are known today (Schwarz 
& Futerman 1996; Yu 2007). This number increases when ceramide lipid variations are 
taken into account. Accumulating evidence indicates that many cellular events, including 
differentiation, growth, signaling, interactions and immune reactions are highly influenced 
by gangliosides, which may lead to malignancies. Positioned in the plasma membrane, 
gangliosides influence and interact with proteins both laterally in the membrane but also 
as surface receptors, being perfectly accessible for antibodies or other ganglioside-
binding molecules.  
 
  
Figure 1. Schematic structure of NeuAc GM3, a common ganglioside in most vertebrate tissues. 
Carbohydrate symbols follow the nomenclature of the Consortium for Functional Glycomics 
(www.functionalglycomics.org/static/consortium/Nomenclature.shtml). 
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1.1.1 Biosynthesis of gangliosides  
The biosynthesis of gangliosides is primarily mediated by specific glycosyltransferases 
which transfer sugar residues to the lipid part. The glycosyltransferases are specific to 
the sugar they transfer, and are grouped into families according to their specificity. 
Interestingly, all glycosyltransferase promoters lack the TATA sequence, hence do not 
have any core promoter element characteristic for house-keeping genes. Although some 
indications relate their transcription to complex developmental and tissue-specific 
regulation, very little is known about how glycosyltransferases are regulated (Zeng &Yu 
2008). Glycosphingolipids are mainly synthesized in the endoplasmic reticulum (ER), 
modified in the Golgi apparatus (Kolter et al. 2002; Merrill 2002) by sequential addition of 
carbohydrate moieties to the lipid molecule, followed by vesicle sorting to fuse with the 
plasma membrane (Maccioni 2007). Gangliosides are assumed to recycle to the plasma 
membrane from early endosomes and a degradation process is thought to take place at 
the late endosomal level (Tettamanti 2004). The biosynthetic pathways of gangliosides 
are shown in Figure 2.  
The synthesis of gangliosides starts with the synthesis of ceramide, the common 
precursor for all glycosphingolipids, in the ER compartment. Aided by a transfer protein, 
CERT, ceramide is then transferred to the Golgi apparatus, and thereafter converted to 
glucosylceramide (GlcCer) (Hanada et al. 2003). By addition of a galactose moiety to 
GlcCer, lactosylceramide (LacCer), the common precursor for almost all gangliosides 
(except for GM4), is formed.  Addition of one sialic acid to LacCer converts this precursor 
molecule to GM3, a reaction catalyzed by sialyltransferase I (ST-I) or GM3 synthase. In 
the same manner, GD3 and GT3 can be generated by further addition of sialic acid 
residues, catalyzed by ST-II or GD3 synthase and ST-III or GT3 synthase, respectively. 
The number of sialic acid residues linked to the inner galactose residue (0, 1, 2, or 3) 
classify the ganglioside into asialo, a-, b-, or c-series (Figure 2). However, only trace 
amounts of gangliosides from the asialo- and c-series are found in adult human tissue 
(Sandhoff & Kolter 2003).  
 
 
     Figure 2. The biosynthetic pathways of gangliosides. Cer, ceramide; SA, sialic acid. 
Ganglioside nomenclature is shown in boxes. Adapted from (Yu et al. 2011). 
 
 
1.1.2 Ganglioside functions 
While gangliosides are primarily present in the plasma membrane, they have recently 
been recognized as functionally important constituents of nuclear membranes (Katoh et 
al. 1993; Saito & Sugiyama 2002; Ledeen & Wu 2004). Knock-out studies in mice have 
been essential for revealing the functions of gangliosides, especially in embryonic 
development and differentiation. Yamashita et al observed that mouse embryo carrying a 
knock-out of the glycosylceramide synthase gene did not survive more than 7.5 days 
(Yamashita et al. 1999). Other examples are studies of mice with knock-down of GM3 
synthase or GM2/GD2 synthase. They exhibit increased insulin sensitivity and 
decreased ability to repair nervous tissues, respectively (Takamiya et al. 1996; 
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Yamashita et al. 2003). Glycosphingolipids (including gangliosides) are key molecules in 
recognition and signaling. Because of the strictly packed backbone, gangliosides are 
able to associate with other types of sphingolipids and cholesterol, therefore forming lipid 
rafts, to which many proteins can associate (Simons & Ikonen 1997; Simons & Toomre 
2000). Organization of gangliosides in membranes will be further discussed in Section 
1.1.3. Since gangliosides have the ability to interact with both sugars and proteins, a 
large variety of events can be triggered or inhibited by these molecules. Cell growth, 
migration, differentiation, adhesion and apoptosis are some examples (Bremer et al. 
1986; Hakomori & Igarashi 1995). These interactions (mainly) involve the carbohydrate 
part of the ganglioside, most importantly the sialic acid residue, making gangliosides 
attractive targets for many pathogens using sialic acids as a way to enter the cell.  
The most common ligand for viruses is Neu5Ac, however, Neu5Gc and 9-O-acetylated 
sialic acids are also specific ligands (Lehmann et al. 2006; Schauer et al. 2011). 
Pathogens binding to gangliosides can be different types of viruses, with the oldest 
example being the influenza virus (Suzuki et al. 1986). Other examples are the 
ganglioside recognition by simian virus 40 (SV40) (Neu et al. 2008) and rotavirus 
(Delorme et al. 2001). A number of toxins can also directly interact with gangliosides, 
including the cholera toxin, Shiga toxin and clostridial neurotoxins (Lencer et al. 1999; 
Stenmark et al. 2008; Sandvig et al. 2014). Gangliosides may also suppress natural killer 
cell cytotoxicity, through interaction between Siglec-7 (sialic acid-binding 
immunoglobulin-like lectin 7), which preferentially binds to gangliosides of the b-series, 
and cells engineered to overexpress GD3 (Nicoll et al. 2003). Melanoma cells have high 
expression levels of GD3 ganglioside, thus the efficiency of NK cell cytotoxicity against 
tumor cells may be suppressed.  
As gangliosides are localized in the plasma membrane, structural characterization of 
anchored gangliosides has been difficult to achieve. De Marco & Woods employed an 
atomic-resolution conformational analysis to study the presentation and conformation of 
the GM3 head-group and the dynamics associated with membrane anchoring in protein 
recognition (DeMarco and Woods 2009).  Changes in the internal structural properties 
were not observed for the membrane-bound GM3 compared to the GM3 head-group in 
solution, however, accessibility of the carbohydrate residues was altered when anchored 
 
(Figure 3). Two known GM3-binding proteins (sialo-adhesin and wheat germ agglutinin) 
were studied in order to determine the importance of carbohydrate accessibility and 
protein recognition. Based on crystal structures of the head-group and proteins, the 
interactions were determined to mainly involve the Neu5Ac residue, since the Glc 
residue had high B-factors and was not in contact with the protein (May et al. 1998). The 
less exposed residues have been suggested to indirectly affect recognition, by ceramide-
Glc and Glc-Gal rotations, altering the Neu5Ac presentation. The properties of the 
hydrophobic ceramide together with the polar Glc residue may also regulate the insertion 
depth, giving an additional effect on antigen presentation (DeMarco & Woods 2009). 
 
1.1.3 Organization of gangliosides in membranes 
There is a great interest in understanding how membrane proteins interact with 
surrounding lipids in a biological membrane, since a growing number of important 
recognition events involve interactions between proteins and glycolipids. In the past 
decade, many studies have focused on the lateral determination of the membrane and it 
is well established that GSLs are able to create order in biological membranes (Sonnino 
et al. 2007). Glycerophospholipids, the main components of biological membranes, are 
highly unsaturated. However, gangliosides are characterized by a rigid and planar 
structure, composed of saturated acyl chains, which can be more tightly packed. 
Membrane sphingolipids can segregate and form “clusters” together with cholesterol, 
also referred to as “lipid rafts”, creating more ordered membrane regions, to which 
proteins associate (Simons & Ikonen 1997; Simons & Toomre 2000; Simons & Sampaio 
2011). Figure 4 shows the suggested interaction between GSLs and cholesterol, where 
a tilted conformation is induced (Nyholm et al. 1990; Yahi et al. 2010). 
The clustering and density of GSLs can also affect antigen specificity. For example, an 
antibody established by immunizing mice with syngeneic B16 melanoma, named M2590, 
reacted only with melanoma and not with healthy tissues (Taniguchi & Wakabayashi 
1984). Remarkably, this epitope was later identified as GM3, an abundant ganglioside in 
membranes of normal cells (Hirabayashi et al. 1985). Further studies showed that a 
ganglioside density above threshold value was required for reactivity, suggesting that 
this antibody recognized a cluster of GM3 (Nores et al. 1987). These results indicate that 
 
ganglioside antigens can be differently organized in tumor cells compared to normal cells 
and that some ganglioside antigens are fully antigenic when organized in clusters, but 
fail to bind antibodies when the density is under the threshold value (Hakomori et al. 
1981; Nores et al. 1987).  
 
 
 
 
Figure 4. Interaction between glycosphingolipid and cholesterol, important constituents of lipid 
rafts. Adapted from (Yahi et al. 2010) in an extension of earlier work by (Nyholm et al. 1990). 
 
 
1.1.4 Gangliosides and membrane protein signaling 
It has been suggested that activation of membrane proteins can be influenced by lipid 
cluster association. As the sphingolipids have unique properties, bearing a carbonyl 
oxygen, a hydroxyl group and an amide nitrogen, thus able to act as both donors and 
acceptors for hydrogen bond formation (Pascher 1976), this results in a variety of 
interaction possibilities. As previously mentioned, more stable interactions can be formed 
due to a more ordered lipid surrounding. It has been suggested that tightly packed 
gangliosides, associated to the protein, may cause conformational changes of the 
protein, influencing the activity. The carbohydrate moiety of the ganglioside may interact 
directly with amino acids of the extracellular part of the protein or interact with sugar 
residues of a glycosylated protein.  
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Most growth factor receptors are known to be regulated by gangliosides (Miljan et al. 
2002). Here, I would like to discuss two examples of membrane proteins important in 
cancer research, EGFR and VEGFR (Table 1). A number of cancers have over-
expressed or over-activated EGFRs in their membrane (Kuan et al. 2001; Lynch et al. 
2004; Walker et al. 2009). Another important factor for tumor progression is the growth of 
new blood vessels. Tumor cells produce and release VEGF, that will stimulate VEGFR, 
resulting in proliferation and migration of vascular endothelial cells (Ferrara & Kerbel 
2005). The EGFR undergoes dimerization by ligand binding, resulting in an 
autophosphorylation of tyrosine residues at the C-terminus of the protein (Downward et 
al. 1984). This initiates downstream signaling, leading to adhesion, cell migration and 
proliferation (Oda  et al. 2005).  
 
 
       Table 1. List of gangliosides affecting the growth factor receptors EGFR and VEGFR. 
 
The ganglioside GM3 is a well known regultator of the insulin receptor (IR), but also has 
an inhibitory effect on the epidermal growth factor receptor (EGFR) and the vascular 
endothelial growth factor receptor (VEGFR), while the ganglioside GD1a strongly induce 
VEGFR-2 activation (Bremer et al. 1986; Nojiri et al. 1991; Mukherjee et al. 2008). 
Moreover, the proangiogenic effects of GD1a could efficiently be reduced by GM3 
Ganglioside  Growth factor receptor References 
GM3 EGFR (Mirkin et al. 2002; Yoon et al. 2006; Kawashima et al. 2009; Coskun et al. 2011) 
GM1 EGFR (Mirkin et al. 2002; Hofman et al. 2009) 
GM2 EGFR (Miljan et al. 2002; Zurita et al. 2004) 
GM4 EGFR (Miljan et al. 2002) 
GD3 EGFR (Zurita et al. 2004; Wang & Yu 2013)  
GD1a EGFR (Mirkin et al. 2002; Liu et al. 2004) 
GT1b EGFR (Mirkin et al. 2002) 
GM3 VEGFR (Mukherjee et al. 2008; Chung et al. 2009) 
GD1a VEGFR (Liu et al. 2006; Mukherjee et al. 2008) 
GD3 VEGFR (Zeng et al. 2000) 
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(Mukherjee et al. 2008). The latter has been suggested to inhibit VEGFR-2 activation by 
blocking both binding of VEGF and dimerization through a direct interaction with the 
extracellular domain of VEGFR (Chung et al. 2009). The molecular interaction between 
the EGFR and GM3 is not fully elucidated, although it has been studied extensively. It 
has been shown that the inhibition of EGFR activation by GM3 involves binding between 
GlcNAc-terminated N-glycans on the EGFR and the GM3 oligosaccharide, suggesting a 
carbohydrate-to-carbohydrate interaction (CCI) (Yoon et al. 2006; Yoon et al. 2006; 
Kawashima et al. 2009). Additionally, evidence is accumulating that ganglioside 
organization in the membrane may affect localization and activation of growth factor 
receptors. As cellular biological membranes are complex, and the dynamics are difficult 
to study, Coscun et al. reconstituted EGFR into proteoliposomes with defined lipid 
composition, forming variants with either uniform liquid-disordered (ld) membrane 
phases or a combination of disordered and ordered (ld/lo) domains, to which 
gangliosides could be added (Coskun et al. 2011). Interestingly, they show that GM3 had 
a strong inhibitory effect of EGFR activation, without interfering with ligand-binding, but in 
ld/lo proteoliposomes only (Coskun et al. 2011).  
 
1.1.5 Gangliosides and cancer 
Gangliosides play important roles in many normal physiological processes, such as cell 
growth, differentiation and embryogenesis (Yamashita et al. 1999), as well as in 
pathological events such as tumor malignancy and progression (Hakomori 1996). 
Formation of tumors results from autonomous uncontrolled proliferation of neoplastic 
cells, while metastasis occurs when tumor cells are released from the primary tumor and 
continue to proliferate at a distant site. Multiple factors affect these processes, in which 
gangliosides may serve both as inhibitory and stimulating molecules. For instance, It has 
been shown that highly metastatic melanoma cells have high expression levels of GD3 
in contrast to poorly metastatic cells or the normal counterpart, melanocytes, expressing 
very low levels of GD3 (Carubia et al. 1984; Ravindranath et al. 1991; Merzak et al. 
1994), suggesting a role in transforming melanocytes to melanomas and promoting 
metastasis. Table 2 lists some of the gangliosides found in human tumors.  
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Table 2. Gangliosides expressed in human cancer cells 
 
Gangliosides are also actively shed from the tumor to the microenvironment. These 
gangliosides can interact with proteins or be incorporated into the membrane of other 
cells, leading to signaling events (Li & Ladisch 1991; Chang et al. 1997; Rusnati et al. 
1999). Tumor cells shed gangliosides in greater quantities than normal cells. Notably, 
exogenous GD3 added to the culture medium of glioma cells stimulate the release of 
VEGF (vascular epidermal growth factor) (Koochekpour et al. 1996). Other possibilities 
to mediate cell-cell interaction and signaling functions are ganglioside (sialic acid) 
recognition by Siglecs (Crocker et al. 2007). The function of ganglioside as suppressor of 
the antitumor immune response is supported by many studies. For instance, tumor-
associated gangliosides decrease the activity of several immune cells, such as T and B 
cells, natural killer cytotoxicity and active dendritic cells (Ando et al. 1987; Grayson & 
Ganglioside  Structure  Cancer type References  
NeuAc GM3 Neu5Ac(2-3)DGal(1-
4)DGlc(1-1)Cer 
Melanoma, NSCLC, 
breast carcinoma, 
renal carcinoma 
(Pukel et al. 1982; Ravindranath, 
et al. 1991; Marquina et al. 1996; 
Morton & Barth 1996; Kudo et al. 
2003; van Cruijsen  et al. 2009) 
NeuGc GM3 Neu5Gc(2-3)DGal(1-
4)DGlc(1-1)Cer 
Colon cancer, 
retinoblastoma, 
melanoma, breast 
carcinoma, 
neuroectodermal 
cancer, Wilms tumor 
(Higashi et al. 1985; Marquina et 
al. 1996; van Cruijsen et al. 2009;  
Scursoni et al. 2009 
; Scursoni et al. 2011)
 
GM2 DGalNAc(1-4)[Neu5Ac(2-
3)]DGal(1-4)DGlc(1-1)Cer 
Melanoma, 
neuroblastoma, 
SCLC, t-ALL, breast 
carcinoma, renal 
carcinoma 
(Brezicka et al. 1989; Marquina et 
al. 1996; Morton & Barth 1996; 
Okada et al. 1996; Kudo et al. 
2003; Hettmer et al. 2005; Chung 
et al. 2009) 
GM1 DGal(1-
3)DGalNAc[Neu5Ac(2-
3)]DGal(1-4)DGlc(1-1)Cer 
SCLC, renal 
carcinoma 
(Brezicka et al. 1989; Marquina et 
al. 1996) 
GD3 Neu5Ac(2-8)Neu5Ac(2-
3)DGal(1-4)DGlc(1-1)Cer 
Melanoma, 
neuroblastoma, 
glioma, SCLC, t-
ALL, breast 
carcinoma 
(Pukel et al. 1982; Cheung et al. 
1985; Mujoo et al. 1987; 
Ravindranath et al. 1991; 
Hakomori & Igarashi 1995; 
Morton & Barth 1996; Okada et al. 
1996; Hettmer et al. 2005) 
GD2 DGalNAc(1-4)[Neu5Ac(2-
8)Neu5Ac(2-3)]DGal(1-
4)DGlc(1-1)Cer 
Melanoma, 
neuroblastoma, 
glioma, SCLC, t-ALL 
(Pukel et al. 1982; Cheung et al. 
1985; Mujoo et al. 1987; Brezicka 
et al. 1989; Ravindranath et al. 
1991; Morton & Barth 1996; 
Okada et al. 1996; Hettmer et al. 
2005) 
 

Ladisch 1992; Biswas et al. 2006). T-cell dysfunction is promoted by the ganglioside 
GM2, however, an antibody targeting GM2 blocked 50-60% of T-cell apoptosis (Biswas 
et al. 2006). These observations may explain, at least partly, how tumor-associated 
gangliosides may contribute to malignancy and progression. 
Many of the tumor-associated gangliosides are also found in normal healthy tissues, but 
are over-expressed in tumors. Interestingly, the sialic acid Neu5Gc is found in several 
tumor types. Among all sialic acid forms, Neu5Ac and Neu5Gc are the most abundant, 
however, humans are a notable exception. Due to a 92-bp deletion in the gene coding 
for CMP-Neu5Ac hydroxylase (CMAH), humans lack a functional enzyme required for 
generation of Neu5Gc. However, Neu5Gc is present in fetal tissues and malignant cells 
(Hirabayashi et al. 1987; Kawachi & Saida 1992; Marquina et al. 1996). For this reason, 
Neu5Gc was earlier assumed to classify as an “oncofetal” antigen, being expressed in 
fetus, suppressed during adult life and re-expressed in malignant cells. As humans lack 
the putative active site in the enzyme, other explanations must be found for this change 
in carbohydrate profile. Diet incorporation and hypoxic conditions have been described 
to increase the levels of NeuGc (Irie et al. 1998; Varki 2001; Tangvoranuntakul et al. 
2003; Yin et al. 2006). Interestingly, it has been shown that sera from healthy humans 
contain antibodies recognizing glycoconjugates containing Neu5Gc. These antibodies 
are called Hanganutziu-Deicher (HD) antibodies, as they were first (and separately) 
described in the 1920s by Hanganutziu (Hanganutziu 1924) and Deicher (Deicher 1926) 
(as cited in (Merrick et al. 1978)). They attract complement molecules to malignant cells 
(Zhu & Hurst 2002; Ravindranath et al. 2007), and the levels HD antibodies in serum 
decreases with age, which may correlate with cancer risk increasing with age 
(Ravindranath et al. 2007). Characteristic for natural antibodies is that they recognize 
highly conserved antigens (Cojocaru et al. 2009). Importantly, auto-antibodies against 
tumor-associated antigens can arise and be detected early, before symptoms occur 
(Zhang et al. 2003; Storr et al. 2006; Chapman et al. 2008).  
 
 
1.2 Cancer Immunotherapy 
Cancer is among the most life-threatening diseases in industrial countries, causing 25% 
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of mortalities, even though standard therapies, including surgery, chemotherapy and 
radiation are well established. Current therapies rely on drugs killing dividing cells or 
blocking cell division, which also has severe effects on normal proliferating cells. An 
alternative treatment, cancer immunotherapy, has grown significantly during the last 
decades, and was selected by Science as the breakthrough of the year 2013. The 
immune responses to tumors are mainly specific to tumor antigens and will not injure 
healthy cells. Approaches applied in immunotherapy are based on complementation 
activation or stimulation of the immune system via a variety of compounds, including 
cytokines, vaccines, effector cells or antibodies. The intention of cancer immunotherapy 
is to augment the weak host immune response to the tumor (active immunity) in order to 
fight the disease. More than 100 years ago, a surgeon in New York (W.B Coley) did 
pioneering work in immunotherapy by vaccinating sarcoma patients with a mixture of 
attenuated streptococcal and staphylococcal bacteria, also known as Coley’s vaccine, 
resulting ina febrile reaction and reduction in size of tumor mass (Coley 1991). During 
the last decades, modern cancer immunology was reinforced mainly as a result of three 
discoveries. First, Kohler and Milstein (Kohler & Milstein 1975) developed the hybridoma 
fusion technology and paved way for new, target-specific molecules, monoclonal 
antibodies. Second, the establishment of molecular biology allowed the characterization 
of cancer-associated signaling cascades, such as the epidermal growth factor signaling 
in breast cancer (Cohen et al. 1980). Third, the discovery of cytokines added an extra 
tool in cancer treatment (Smith et al. 1983). 
 
1.2.1 Passive immunotherapy 
Passive immunotherapy involves the transfer of immune effectors, such as antibodies 
and tumor-specific T cells, into patients. Currently hundreds of different monoclonal 
antibodies are being considered, either in experimental pre-clinical studies or in human 
clinical trials, and a few anti-tumor monoclonal antibodies have been approved for 
clinical use. 
In early human trials, anti-tumor antibodies originated from mice resulted in a frequently 
occurring immune response against the mouse antibody. This reaction, known as the 
HAMA response, induce human anti-mouse antibodies, resulting in rapid clearance of 
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circulating therapeutic antibodies, thus abrogating the efficacy of the treatment (Klee 
2000). This issue has been partially solved by the use of chimeric or “humanized” anti-
tumor antibodies, consisting of a combination of murine variable regions or 
complementarity-determining regions, (CDRs), with human constant domain (Fc) 
(Morrison et al. 1984; Riechmann et al. 1988) (Figure 5). 
 
 
Figure 5. A schematic representation of an antibody. 
 
1.2.1.1 Cell death killing mechanisms 
Monoclonal antibodies can cause tumor cell death using different mechanisms. The 
most common ‘classical’ mechanisms include antibody-dependent cellular cytotoxicity 
(ADCC), complement-dependent cytotoxicity (CDC) and induction of apoptosis (Liu et al. 
2008; Chan & Carter 2010; Weiner et al. 2010). Tumor-cell killing by ADCC is triggered 
by Fc-Fc receptor interaction. The Fc receptors are present on immune effector cells, 
such as macrophages, neutrophils and natural killer cells, mediating lysis or 
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phagocytosis of the tumor cells. CDC is dependent on the recruitment of the complement 
component C1q by the antibody. When the complement initiator C1q is bound to the Fc 
region of the antibody, a proteolytic cascade to activate the complement system will be 
triggered. This can lead to membrane attack complex formation or trigger cell-mediated 
tumor-cell lysis or phagocytosis. Although other types of mechanisms are known, they 
are rarely described in the literature. For example, some killing mechanisms can induce 
cytotoxicity in an Fc-independent manner, without causing the morphological changes 
often occurring in apoptosis-related cell death. Such novel mechanisms have been found 
to be associated with membrane lesions. These lesions were observed when antibodies, 
in an unaided and non-apoptotic way, killed tumor cells (Hellstrom et al. 1990; Garrigues 
et al. 1993; Matsuoka et al. 1995; Bhat et al. 1996; Zhang, Xu et al. 1998; Ma, Zhang et 
al. 2001).  
 
1.2.1.2 Anti-NeuGc GM3 
Several antibodies targeting tumor-associated gangliosides are under investigation in 
pre-clinical or clinical studies, also including molecular vaccines. Two examples are 14F7 
and chP3, both specifically recognizing Neu5Gc GM3, but not the abundant Neu5Ac 
GM3, even though these molecules have highly similar structures. 14F7, discussed in 
this thesis, is a promising antibody with remarkable features. For instance, it has been 
tested for a strong anti-tumor effect, comparable to standard chemotherapy treatment 
(Carr et al. 2002). The binding affinity for this antibody is within the nanomolar range, 
and it generates an anti-idiotypic antibody, 4G9, which in turn provokes an efficient anti-
anti-idiotypic (Ab3) response (Rodriguez et al. 2003). 
In order to achieve more advantageous properties of therapeutic antibodies, such as an 
extended binding specificity or higher affinity, it is essential to characterize the binding 
interactions between the antibody and its antigen (or anti-idiotypic antibody), thus 
providing a basis for engineering the interface. The crystal structure of the 14F7 Fab was 
solved by Krengel et al. (Krengel et al. 2004) but to date, no crystal structures of the 
antibody in complexes with its antigen or anti-idiotypic antibody are available. However, 
docking and phage display studies have contributed to understand the recognition 
mechanisms (Agostino et al. 2012; Rojas et al. 2013). 
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1.2.2 Active immunotherapy 
The historic findings by Coley suggested that the immune system is able to attack the 
tumor cells, provided that the malignant cells are recognized in an immunogenic context 
(Coley 1991). Early attempts to boost the immune system relied on non-specific immune 
stimulation. Today, cancer vaccines are targeted because they do not just boost the 
immune system in general, but they direct it specifically towards the tumor. Examples of 
different components of cancer vaccines include killed tumor cells, purified tumor 
antigens, anti-idiotypic antibodies, professional antigen-presenting cells (APCs), DNA or 
viral vectors. They can also be cytokine- and co-stimulator-enhanced vaccines. In many 
cases, the vaccines are combined with other substances (adjuvants), in order to boost 
the immune response further.  
 
1.2.2.1 “GM3 mimic” 
As a tool in cancer immunotherapy, idiotypes (Ids) have gained in interest over the last 
three decades. An idiotype is defined as the set of antigenic determinants close to the 
antigen-binding site of an antibody (Oudin & Michel 1963; Grey et al. 1965). These 
determinants are able to elicit an immune response both at the humoral and cellular 
level. The “idiotypic network theory” was developed by the Danish immunologist Nils 
Jerne in the 70’s (Jerne 1974) and together with Bona’s “regulatory idiotope” (Victor-
Kobrin et al. 1985) and Couthino’s “second generation networks” (Varela & Coutinho 
1991) fundamentally impacted the concept of immune regulation. These anti-idiotypic 
hypotheses are often weakly supported by experimental evidence, but regardless of this, 
anti-idiotypic antibodies that can “mimic” antigens of protein or non-protein type, are 
considered attractive in cancer immunotherapy. The antigen-induced antibody (Ab1) 
recognizes the epitope of the antigen through its variable regions, including the heavy 
(VH) and light (VL) chains. Anti-idiotypic antibodies (Ab2s) are directed against the 
variable part of Ab1 (Figure 5). Anti-idiotypic antibodies (Ab2s) are classified into 
different types based mainly on functional properties of the antibody, such as the ability 
of inhibiting the interaction between Ab1 and the antigen, but also the capability to 
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induce anti-anti-idiotypic antibodies (Ab3s). For example, the Ab2 type is not able to 
inhibit the Ab1-antigen interaction, thus should bind to non-variable parts of the Ab1. In 
contrast, the Ab2 will compete for the binding site and therefore inhibit interaction, but is 
incapable of generating Ab3 antibodies when used as an immunogen. As antigen 
mimicry is ultimately the desired feature when it comes to Ab2, the Ab2, which are 
carrying an "internal image" of the original epitope, are considered the most promising 
vaccine candidates (Jerne 1974; Coutinho 1995). Several anti-idiotypic antibodies 
targeting gangliosides are under investigation (Bhattacharya-Chatterjee et al. 2000). For 
example, a vaccine against GD3, using an Ab2 type of anti-idiotypic antibody mimicking 
GD3, has shown increased survival in small-cell lung carcinoma patients (Chapman 
2003). Moreover, B cells derived from a relapse-free neuroblastoma patient treated with 
an anti-GD2 antibody, were used to generate Ab2 antibodies (GK8) with vaccine 
potential (Mueller et al. 1990; Uttenreuther-Fischer et al. 2006). 14F7 and P3 are 
monoclonal antibodies targeting the NeuGc GM3 ganglioside. They both generate 
several Ab2s (Vazquez et al. 1998; Rodriguez et al. 2003; Lopez-Requena et al. 2007; 
Rodriguez et al. 2007). The most studied one is Racotumomab (1E10). It was first 
thought to be an Ab2 since it is able to inhibit the Ab1 (P3)-antigen binding, but when 
injected into mice, the Ab3s were unable to recognize the antigen (Vazquez et al. 1998). 
Later it was proven that this was a species-dependent reaction and Ab3s with the same 
specificity as P3 (so-called Ab1’), are induced only in species where the antigen (NeuGc) 
is non-self. Racotumomab is therefore able to “mimic” NeuGc GM3 only in humans and 
chicken (Hernandez et al. 2005). It is currently in clinical trials (approved in Cuba and 
Argentina), successfully completed a proof-of-concept in advanced non-small cell lung 
cancer (Vazquez et al. 2012). 
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 Figure 5. Different types of anti-idiotypic antibodies. Adapted from (López-Requena 2009). 
 
 
1.3 Cancer and hypoxia  
Hypoxia is defined as oxygen levels below 5%, often observed in advanced tumors, but 
also in embryonic cells, as an essential factor for differentiation and proliferation 
processes (Vaupel et al. 1989; Lee et al. 2001; Forristal et al. 2010; Prado-Lopez et al. 
2010).  Approximately 90% of all known cancers are solid tumors (Brown 2000). During 
the process of tumor progression (proliferation, invasion and metastasis), rapid growth of 
the tumor is associated with changes in the cellular microenvironment. These changes 
are mainly due to inadequate oxygen supply, resulting in regions in the tumor where the 
oxygen concentration is considerably lower than in surrounding healthy tissues. This is 
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referred to as tumor hypoxia, and is a common characteristic of advanced tumors. 
Tumor hypoxia is considered an adverse prognostic indicator and a therapeutic problem, 
making tumors more resistant to ionization radiation and chemotherapy (Burnet et al. 
1994; Brown 2000; Shannon et al. 2003). More recently, alteration of intra-tumoral 
oxygen levels has been associated with malignant progression (Brown & Giaccia 1998; 
Sutherland 1998; Semenza 2000). Moreover, sustained tumor hypoxia may also trigger 
cellular alterations, causing a more aggressive phenotype (Brizel et al. 1996; Hockel et 
al. 1998; Walenta et al. 2000). A well-known character of malignant and invasive cells is 
an altered glucose metabolism. Glycolysis is inhibited by the presence of oxygen, 
allowing mitochondria to oxidize pyruvate to CO2 and H2O, a process termed the 
‘Pasteur effect’ (Racker 1974). Cancer cells can convert glucose to lactate when oxygen 
is present, a process referred to as ‘aerobic glycolysis’ or the ‘Warburg effect’, after Otto 
Warburg, who first observed this phenomenon in the 1920s (Warburg et al. 1927). This 
resulted in the hypothesis that cancer may be caused by mitochondrial dysfunction. 
Hypoxia induces changes in the tumor proteome, allowing the tumor to successfully 
adapt to low oxygen levels and survive in a harsh environment. Details about this 
adaptation, which simultaneously provokes more aggressive tumors, are discussed in 
this thesis. 
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2. Experimental techniques   
2.1 Mass spectrometry 
2.1.1 Instrumentation 
Mass spectrometry is a sensitive technique to identify and quantify molecules based on 
their mass and charge (m/z). Although this technique was developed almost a century 
ago, ionization of larger molecules, such as proteins was not possible until 1981 (Barber 
et al. 1981). Macromolecule ionization methods were then developed, such as 
electrospray ionization (ESI) and matrix-assisted laser desorption/ionization (MALDI), 
which enabled scientists to study protein structure and identify unknown proteins by the 
use of mass spectrometry (Tanaka et al. 1988; Fenn et al. 1989; Chowdhury et al. 1990). 
Both ESI and MALDI are soft ionization techniques, allowing the analysis of more fragile 
molecules such as proteins, DNA and carbohydrates. The electrospray ion source is 
easily connected to liquid chromatography (LC), which simplifies the analysis of complex 
protein mixtures. An “in-line” system elutes analytes through the column at different 
rates, which are immediately analyzed by MS. The MALDI technique generates far fewer 
ions that are multiply charged. Common for all mass spectrometers is that they all have 
an ion source, a mass analyzer and an ion detector, although these components vary 
depending on the mass spectrometer type. The instrument must also be connected to a 
vacuum pump in order to control the pressure within the instrument, as low pressure (10-
6 to 10-8 torr) is necessary to limit the number of ion collisions. In a typical experiment, 
the sample, which can be in liquid or dry form, is ionized and in some cases vaporized 
by the ion source, which could be ESI or MALDI. During this process, the molecules 
receive a charge, allowing acceleration throughout the system. Using an ESI source, the 
ionization occurs when the inlet stream is released from a capillary that has a voltage 
applied to it. A spray of charged droplets is formed, which are desolvated through stages 
of decreasing pressure. MALDI is based on co-crystallization of the sample within an 
organic matrix, such as –cyano-4-hydroxycinnamic acid or sinapinic acid on a metal 
plate. The crystals are then irradiated with laser pulses, resulting in a photoexcited 
matrix that ionizes the analyte via proton transfer, producing ions in (mostly) singly 
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charged analyte ions in gas phase. The ions will then be directed to the mass analyzer, 
which can be of different types (e.g. time-of-flight (TOF), ion traps or quadrupoles). It 
provides an electrical and/or magnetic field to the charged ions, which deflects, based on 
the mass and charge, the path of the individual ions. The low pressure is essential to not 
alter the path or charge of the ions. These will then hit the ion detector, which are often 
microchannel plates or electron multipliers. As the ions hit the detector (a metal plate), a 
cascade of electrons is emitted, resulting in a measurable current (Finehout & Lee 
2004). MS/MS (also known as tandem MS or MS2) is a method frequently used in 
biological MS to reveal structural details or amino acid sequences. Ions with a selected 
m/z (known as precursor ions) are selected, fragmented and the resulting product ions 
are measured. This can be achieved using two mass analyzers separated by a collision 
cell. Commonly used mass analyzers are ion trap, TOF, quadrupole and the Fourier 
transform-ion cyclotron resonance analyzer. For instance, using a MALDI TOF/TOF, two 
TOF analyzers are employed and separated by a collision cell. The collision cell is 
pressurized with a non-reactive gas (e.g. helium), in which the ions are fragmented via 
collision-induced dissociation (CID). The product ions are thereafter reaccelerated before 
entering the second TOF analyzer for final analysis.   
 
2.1.2 Protein identification 
Protein identification methods include a combination of peptide mass fingerprinting and 
amino acid sequencing using MS/MS. Since the amino acid sequence is unique for each 
protein, proteolytically cleaved peptides provide a “fingerprint” of the protein. Typically, 
proteins are separated prior to digestion, either by LC or gel electrophoresis. In an 
unknown protein identification experiment, the protein is alkylated and reduced, and a 
subsequent digestion by a sequence-specific enzyme (e.g. trypsin) is performed. The 
resulting peptides are measured with MS to obtain a list of peptide masses, which is then 
entered into a search program (e.g. Mascot). A comparison between the amino acid 
sequences of proteins obtained from databases such as Swiss-prot or NCBI and the list 
of peptide masses from the sample result in a list of possible proteins and probability 
values. In order to increase the probability of a correct match, an MS/MS analysis can be 
performed. Here, a specific m/z is selected and fragmented. As the bonds between the 
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amino acids are the weakest, this results in a spectrum with peaks that represent 
peptides that differ only in the number of amino acids they contain. The mass differences 
between the peaks can identify the amino acid sequence of the peptide.   
 
2.1.2 Protein quantification 
Quantitative proteomics relies on the ability to detect small changes in peptide 
abundance in response to an altered state (Ong & Mann 2005). Quantitative proteomics 
can be relative or absolute, where fold changes in different samples and absolute 
amounts of proteins are determined, respectively. Quantification by proteomics was 
previously based on separation by 2D gels, where differences could be visualized by the 
intensity of spots (Bantscheff et al. 2007; Schulze & Usadel 2010). Label-free methods 
can be used for relative quantification, including spectral counting and peptide peak 
intensity measurements. These methods are based on comparing the number of spectra 
from the same protein between different samples and comparing peak intensity 
belonging to a given protein, respectively. Another approach is stable isotope labeling, 
which is based on the introduction of a tag with a mass difference that does not affect 
the chemical properties of the protein but only affects the mass of the protein. The 
labeling can be metabolic, involving introduction of isotopes to whole cells through the 
medium, or chemical, where the isotope is introduced by a chemical reaction. A number 
of chemical labeling tags are available, including isotope-coded affinity tags (ICAT), 
isotope-coded protein labels (ICPL), and isobaric tags for relative and absolute 
quantification (iTRAQ). Stable isotope labeling by amino acids in cell culture (SILAC) is a 
metabolic labeling method, allowing quantitation of very small changes in protein levels. 
This method is discussed in detail in Section 2.2. 
 
 
2.2 Proteomic analysis 
Proteomics has considerably grown as a field over the recent years. Studies in 
quantitative proteomics have traditionally been performed using 2D gel electrophoresis, 
recording alterations in the staining pattern derived from two cell populations in different 
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states. Recently, an isotope labeling approach was developed, so-called ‘stable isotope 
labeling by amino acids in cell culture’ (SILAC) (Ong et al. 2002). This is a relative 
quantification method that compares protein or peptide abundance between samples. In 
SILAC, two cell populations are grown in identical media in all respects except that one 
of them contains a natural ‘light’ and the other a ‘heavy’ form of a particular amino acid 
(e.g. 12C6 L-lysine or 13C6 L-lysine). With each cell doubling, each copy of this particular 
amino acid (e.g lysine) will be replaced by its isotope-labeled analog. After complete 
incorporation, the two cell populations are treated differently. Finally, equal amounts of 
the cell lysate from both cell populations are combined for sample processing and 
subsequent separation by SDS-PAGE. Trypsin is used to digest the protein for MS 
analysis and quantitation of isotopic peptide pairs. Quantitative proteomic analyses rely 
on MS in order to identify and quantify the peptides (as spectrum), although tandem 
mass spectrometry is essential for identification of the peptide (protein). During the first 
round (MS1), the precursor ion spectrum represents all ionized peptides produced. In the 
second round (MS2), selected ions undergo collision-induced fragmentation (CID), 
resulting in a fragment ion spectrum for each precursor ion. These spectra are thereafter 
assigned peptide sequences based on database comparison. In this thesis, SILAC 
analysis was employed to study protein alteration as a response to hypoxic conditions 
and anti-tumor antibody treatment. Both experiments (manuscript I and III) were 
performed using HeLa cells grown in Dulbecco’s modified Eagle’s medium (DMEM) high 
glucose, supplemented with 10% dialyzed fetal bovine serum (FBS)(F6178-Sigma), 1% 
pencillin/streptomycin and either 13C615N4 L-arginine (89990-Fisher) and 13C6 L-lysine 
(89988-Fisher) or media containing natural L-arginine (89989-Fisher) and L-lysine amino 
acids (89987-Fisher). After at least five cell doublings, the two cell populations were 
subjected to treatment. For the hypoxia experiment (described in manuscript I), one 
population of HeLa cells was grown under hypoxic conditions (1%O2) in an InVivo2 400 
multi-gas incubator box (Ruskinn Technology, UK), while the other population was grown 
under normoxic conditions (19%) for 72 h. During the whole experiment, oxygen 
consumption was measured using an automatized oxygen sensor (Unisense, Denmark) 
starting measurements of the oxygen concentration above the medium and proceeding 
until it reached the cell surface. This procedure was repeated every 2 h, giving the real 
pericellular oxygen concentration from the last point in each measured profile. Combined 
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with cell density, calculated from pictures taken every 24 h with an inverted microscope 
(Nikon TS100, Japan) and a Paxcam3 camera (MIS, IL, USA), oxygen consumption per 
cell was defined. For the antibody treatment experiment (manuscript III), one population 
of HeLa cells was incubated with monoclonal anti-tumor 14F7 mAb in 37°C for 3 h, 
kindly provided by the Center of Molecular Immunology (CIM), Havana, Cuba. The other 
cell population was not treated and used as control. The mass spectrometer was 
operated to switch between Orbitrap-MS and LTQ-MS/MS acquisition, allowing isolation 
of up to the seven most intense ions for fragmentation using CID. Protein identification 
and quantification were performed with MaxQuant (Cox & Mann 2008) employing the 
Andromeda search engine (Cox et al. 2011) with the IPI human database including 
common contaminants. For both experiments, at least two quantification events were 
required per protein, in 2 of 3 replicates. Moreover, proteins with a minimum fold change 
of 1.5 and a corrected p-value < 0.05 were considered differentially altered. 
 
 
2.3 Binding studies  
2.3.1 Flow cytometry 
This technique is a laser-based biophysical technology used in cell sorting, cell counting, 
biomarker detection and other purposes. It allows characterization of one cell a time. It is 
commonly performed by staining the cells with fluorescently labeled probes specific for 
the surface molecule of interest, measuring the quantity of fluorescence emitted by the 
cells in real time. The number of cells in a suspension expressing the molecule of 
interest can therefore be determined, by passing the cells one at a time, through a 
fluorimeter with a laser-generated incident beam. By labeling the different cell 
populations with the same probe, the relative amounts of a particular molecule can be 
determined, comparing the amount of fluorescence admitted. The incident laser beam is 
of a designated wavelength, for instance 488 nm for FITC (fluorescein isothiocyanate) 
and PI (propidium iodide). The light emerging from the cell suspension is analyzed for 
forward and side scatter in addition to the wavelength of the fluorochrome labels on the 
cell surface. A simplified model can be used to describe cell size and internal complexity 
 
in terms of forward and side light scattering, respectively. A flow cytometer can also be 
used to study the cell cycle, by which the cells are labeled with a dye that becomes 
fluorescent when bound to DNA. Therefore it is possible to quantify DNA in each cell, as 
the fluorescence is directly proportional to the amount of DNA. Normally, the cells fall 
into three categories: Unreplicated complement of DNA (G1 phase), fully replicated DNA 
complement (G2, twice the amount of DNA in G1 phase) or intermediate amount of DNA 
(S-phase). This method is important not only for understanding normal cell cycle control 
but also to understand loss of normal cell cycle progression, often occurring in cancer.  
In manuscripts I and II, flow cytometry analysis was employed either to determine cell 
cycle progression under hypoxic conditions or to measure the relative amount of the 
antigen NeuGc GM3 in HeLa cells.  
 
2.3.2 Enzyme-Linked ImmunoSorbent Assay (ELISA) 
ELISA is an antibody-based technique used to specifically detect the presence of an 
antigen or another antibody in a sample. The antigen is most commonly coated to a 
polystyrene microtiter plate either by adsorption (non-specifically) or via capturing by an 
already bound antibody. A detection antibody, sometimes enzyme-linked, will form a 
complex with the immobilized antigen. The detection antibody can also be recognized by 
a secondary antibody (linked to an enzyme), which forms a covalent link to its target. 
Different enzymes can be linked to the antibodies, most commonly used are horse 
radish peroxidase and alkaline phosphatase. In order to produce a signal, representing 
the quantity of antigen or antibody binding to the antigen, a substrate is added to the 
plate. This method was used to confirm binding activity of the 14F7 mAb to NeuGc GM3 
(manuscripts III and IV) and to study binding between the anti-idiotypic antibody 4G9 and 
14F7 (manuscript IV). For antibody-antigen binding, a Nunc Polysorp 96 well plate was 
coated with NeuGc GM3 and a dilution series of 14F7 mAb was added to the plate, 
whereas for the antibody-antibody binding a Nunc Maxisorp plate was used to bind the 
one of the protein before dilution series of the other protein was added. An alkaline 
phosphatase conjugated goat anti-mouse IgG was used as secondary antibody and a 
visible signal was generated using the substrate para-nitrophenylphosphate (pNPP).  
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2.3.2.1 Meso scale discovery multi-array (MSD) 
MSD assays follow a workflow similar to that of an ELISA. The plate is coated with the 
capturing agent followed by blocking and adding of samples. Thereafter the detection 
reagent is added and the plate is analyzed. However, MSD has ultra-low detection limits 
and requires minimal sample volumes. Proteoliposomes, containing a combination of 
EGFR and NeuGc GM3 (derived from horse erythrocytes or HeLa cells) were coated on 
the plate and antibodies specifically recognizing NeuGc GM3 (14F7 mAb) and EGFR 
(Nimotuzumab) were tested for binding.   
 
2.3.3 Surface plasmon resonance (SPR) 
This method is used to determine the binding constant in a real-time and label-free 
manner. The SPR method has been used to characterize several molecular interactions, 
including antibody-antigen binding, binding of protein to DNA, small molecules, 
carbohydrates and other proteins. Proteins can bind to their ligands either permanently 
or engage in transient interactions, in which they remain associated temporarily. To 
measure binding, a solution of potentially binding molecules (e.g. proteins) is allowed to 
flow past a biosensor surface coated with immobilized molecules. As molecules bind to 
the sensor surface, the refractive index close to the surface changes. When a light beam 
impinges onto a metal film on the sensor chip at a certain (resonance) angle, the light is 
absorbed by electrons in the metal film, causing the electrons (also known as surface 
plasmons) to resonate. This is monitored in real time and reflects the injected molecules’ 
association or dissociation with the immobilized molecules. SPR was used in manuscript 
IV, both to determine the binding constant of 14F7 to its antigen NeuGc GM3, and to 
investigate if the anti-idiotypic antibody 4G9 interfered with 14F7 mAb binding to the 
immobilized NeuGc GM3. For these experiments, NeuGc GM3 was coated onto a 
Biacore CM5 sensor chip and antibody binding was analyzed with a Biacore 3000 
instrument.  
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2.4 Signaling studies  
2.4.1 Western blotting 
This method is used to determine the relative quantity of a protein within a sample of 
tissue homogenate. Western blotting can also be used to detect the phosphorylation 
state of a protein through the use of phosphotyrosine-specific antibodies. Generally, the 
mixture of proteins is first analytically separated, typically by SDS-PAGE. The separated 
proteins are then transferred from the gel to a support membrane (nitrocellulose or 
polyvinylidene difluoride (PVDF)) by electrophoresis such that the membrane acquires a 
copy of the array of proteins present in the gel. The protein on the membrane can then 
be identified using a primary antibody, specific for the protein of interest, and thereafter a 
species-specific (labeled) secondary antibody, directed against the primary antibody. 
The secondary antibody is detected by colorimetric, chemiluminiscent, radioactive or 
fluorescence detection. Western blotting was used in manuscript II to confirm the 
proteome analysis results, and in previous and ongoing work, studying the effect of 
NeuGc GM3 on EGFR autophosphorylation.  
 
2.4.1.1 Proteoliposomes  
Biological systems are complex and membrane protein and lipid studies in these 
systems are therefore challenging. In order to bypass cellular complexity when 
addressing the role of gangliosides for EGFR activity, proteoliposomes were produced. 
Using a minimal system with defined lipid composition, the lipid environment and its 
importance in receptor modulation could be investigated. The lipids (1,2-dioleoyl-sn-
glycero-3-phosphocholine (DOPC), N-stearoyl-D-erythro-sphingosylphosphorylcholine 
(SM) and cholesterol) were mixed in two different compositions (37.5/37.5/25 or 80/15/5 
mol%) and dried under a nitrogen stream. The gangliosides NeuAc GM3 and NeuGc 
GM3 (0.5 mol%) were added to the membrane systems. Multilamellar vesicles were 
produced by adding HEPES liposome buffer (HLB) and shaking at 58°C. To achieve 
unilamellar vesicles, freeze-thaw cycles and extrusion were performed. To reconstitute 
human EGFR into the liposomes, the liposomes were first fully solubilized with CHAPS 
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(3-[(3-cholamidopropyl)dimethylammonio]-1-propanesulfonate), and then incubated with 
the receptor. Samples were shaken and sonicated repeatedly and the detergent was 
removed by dialysis. The proteoliposomes were incubated with anti-NeuGc GM3 
antibodies (14F7, P3) in order to target the possible activator/inhibitor. Western blotting 
was thereafter performed using antibodies specific for phosphorylated sites or the C-
terminus of the EGFR. 
 
 
2.5 Structural proteomics 
Structural proteomics is a combination of mass spectrometry techniques and protein 
chemistry. It is an approach for fast and efficient molecular characterization of protein-
protein interactions. The techniques used in structural proteomics include limited 
proteolysis, crosslinking, chemical protein modification and hydrogen/deuterium (HDX) 
exchange, all followed by mass spectrometric analysis. These methods are often used 
for complementary analysis, in parallel to classical structural biology methods such as X-
ray crystallography and NMR allowing the study of protein-protein interactions under 
native conditions, often of proteins of biomedical importance. Chemical modification, 
HDX and limited proteolysis can provide direct information about exposed protein 
surfaces, while chemical cross-linking can provide information on inter- or intra-protein 
interactions and distances. None of these methods can by themselves provide structural 
information, but a combination with mass spectrometry is required. Structural proteomics 
therefore demands a highly inter-disciplinary environment between protein and analytical 
chemistry, biomedical and biological sciences.  
 
2.5.1 Chemical cross-linking mass spectrometry (CXMS) 
Mass spectrometry has become and important tool in both protein and protein complex 
structure elucidation. Chemical cross-linking mass spectrometry (CXMS) can provide 
low-resolution analysis and works through covalently binding a linker of a defined size 
between two amino acids in close proximity to each other. Subsequent digestion (e.g. 
trypsination) of the protein, followed by MS analysis, gives information about how 
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proteins interact with each other through the distal restraints set by the linker (Sinz 2003; 
Singh et al. 2010). Several crosslinkers of varying length and reactive sites are available, 
including homolinkers (e.g. Lys/Lys) or heterolinkers (e.g Lys/Arg). This method is not 
going to replace X-ray crystallography as a means to obtain high-resolution structures, 
but it may give low-resolution structural information of proteins and protein complexes. In 
manuscript IV, a Bis(sulfosuccinimidyl) suberate (BS3) crosslinker (21580-Thermo 
Scientific) was used to achieve information about the 14F7/4G9 complex. This is an 
amine-to-amine crosslinker with reactive sulfo-N-hydroxysulfosuccinimide (NHS) esters 
at both ends. Proteins generally contain a number of primary amines, in the side chains 
of lysine residues and the N-terminus, representing suitable targets for the BS3 
crosslinker. 
 
2.5.2 Oxidative footprinting 
This technique is based on hydroxyl radicals that react with proteins to yield stable 
oxidative modifications. These modifications occur in solvent-accessible amino acid side 
chains, some more susceptible to oxidation than others. This method has been 
developed to analyze macromolecules, conformational changes and protein complex 
interaction (Pappin et al. 1993; Sharp et al. 2003; Nukuna et al. 2004). Proteins and 
protein complexes are exposed to hydroxyl radicals reacting with amino acids that are 
both reactive and solvent accessible. Subsequent to oxidation, the proteins are digested 
with site-specific proteases to generate well-defined peptides followed by MS analysis. 
Hydroxyl radicals that are generated using Fenton reagents (Heyduk & Heyduk 1994; 
Sharp et al. 2003) from photo-oxidation of peroxide, radiolysis of water or using electrical 
discharge, are suitable for footprinting experiments (Maleknia et al. 1999; Nukuna et al. 
2004; Sharp et al. 2004; Sharp et al. 2005). Different amino acid side chain products can 
be generated in footprinting experiments, with the most frequently occurring products 
being alcohol or aldehyde groups associated to mass increases of +16 Da or +14 Da, 
respectively. The footprint approach to structural characterization depends on the ability 
to localize the oxidation site within the target peptide. To achieve this, the peptide is 
subjected to fragmentation using CID. To localize the oxidation site, masses of the 
fragments are then analyzed. An ion is dissociated as a result of interaction with a 
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neutral species, most commonly a gas in a collision cell. During the collision, this 
dissociation is brought about by conversion of translational energy of the ion to internal 
energy of the ion. For these experiments, the b-type and y-type fragmentation ions are of 
special interest, as they retain the N- and C-termini of the peptide, respectively. For 
instance, a b-ion retaining only the N-terminal residue is named b1 and the next ion 
(containing two residues) would be denoted b2, and so on. The N-terminal residue is 
identified by the mass of the b1 ion, whereas the mass difference between the b2 and the 
b1 ions identifies the second amino acid. A comparison is made of two MS/MS spectra, 
one containing a modification and one unmodified. Ions retaining the modification will 
show mass shifts relative to the unmodified ion. In protein complex interactions, the 
oxidative footprinting method provides an accurate and sensitive probe of amino acids 
and changes occurring upon complex formation. This method was employed in 
manuscript IV, in order to study antibody-antigen interactions and changes occurring 
during complex formation. Here, hydroxyl radicals were generated by laser photolysis of 
hydrogen peroxide-containing samples of 14F7 mAb and 14F7, preincubated with 
NeuGc GM3 (trisaccharide). The samples were then subjected to digestion and MS 
analysis by MALDI-TOF and LC-MS/MS. 
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3. Summary of manuscripts 
Manuscript I  
Hypoxia strongly affects glycolysis and expression of mitochondrial proteins, as 
shown by quantitative proteomics of HeLa cells 
In this manuscript, we performed a global proteome analysis of HeLa cells in hypoxia. 
Hypoxia is a common feature in advanced tumors and is associated to radio- and 
chemotherapy resistance and malignant progression. SILAC, a quantitative proteomic-
based approach, combined with LC-MS/MS was used to study hypoxic HeLa cells. 
Differences in protein expression of the treated (hypoxia) or non-treated (normoxia) cells 
were analysed by in vivo metabolic labeling of the two cell populations with either the 
‘light’ or the ‘heavy’ form of a particular amino acid, such as L-lysine or L-arginine. This is 
a powerful method to identify and quantify relative alterations in complex protein 
samples. The HeLa cells were cultured in the ‘light’ or ‘heavy’ medium for at least five 
cell doublings in order to ensure sufficient label incorporation into proteins, and 
thereafter subjected to normoxic or hypoxic conditions for 72h. Out of the 3260 proteins 
identified, 137 proteins were found to be regulated according to our criteria. The proteins 
were altered in a wide range, from substantial down-regulation to 18-fold up-regulation. 
Three clusters of proteins were identified, showing significant up-regulation of glycolysis 
and revealing efficient down-regulation of mitochondrial ribosomal proteins and 
translocases of the inner and outer mitochondrial membrane (TIMM/TOMM), processes 
that are most likely synchronized by the ‘master regulator’ of hypoxia, HIF-1. We also 
studied the cell cycle of the cells subjected to hypoxia, and found a cell cycle arrest at a 
restriction point in G1 and a prolonged S phase. This was shown by FACS experiments 
in combination with a cell cycle analysis. Altered proteins involved in these processes 
are discussed in the manuscript. This work contributes to a better understanding of the 
effect of hypoxia on cancer cells and uncovers proteins important for malignant 
progression, with potential for future therapies.  
 
 
 

Manuscript II 
How does hypoxia trigger the expression of NeuGc GM3?  
 
In this manuscript, the hypoxia-induced NeuGc GM3 expression is investigated by a 
combination of FACS and SILAC analysis. NeuGc GM3 not only represents an attractive 
target in cancer therapy but is also a potential prognostic and diagnostic marker. It is 
specific for several types of cancer, but due to a deletion in the gene encoding the active 
site of an enzyme responsible for NeuGc synthesis, this ganglioside is not present in 
healthy human tissues. However, hypoxic conditions have been shown to trigger NeuGc 
expression. In order to study the mechanism by which the hypoxia-induction occurs, 
HeLa cells were placed in normoxic or hypoxic conditions and were thereafter subjected 
to SILAC analysis. We confirmed that hypoxia also triggers NeuGc GM3 expression in 
HeLa cells, and identified proteins with potential of being involved in this up-regulation; in 
particular a protein containing an iron-sulfur cluster was found to be significantly altered. 
This protein, subunit B of the succinate dehydrogenase complex, representing complex 
II of the respiratory chain, was in contrast to many mitochondrial proteins, significantly 
up-regulated. Western blotting was used to confirm up-regulation of SDHB. Interestingly, 
the active site deletion consists of an iron-sulfur cluster (Rieske domain). Whether this 
protein could, provided tumor hypoxia, replace the function of the Rieske domain and 
trigger progression in cancer is yet to be investigated.  
 
 
Manuscript III 
SILAC analysis of HeLa cells treated with the anti-tumor monoclonal antibody 
14F7 
In this manuscript, we study a novel cell death mechanism by which the antibody 14F7 
eliminates cancer cells, using SILAC analysis in conjunction with LC-MS/MS. The 
antibody 14F7 specifically targets the tumor-associated ganglioside NeuGc GM3 and 
has been shown to kill cells unaided, causing lesions in the membrane of tumor cells. 
This novel mechanism does not belong to the ‘classical’ cell death mechanisms, such as 
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antibody-dependent cell-mediated cytotoxicity (ADCC), complement-dependent 
cytotoxicity (CDC) or induction of apoptosis (Liu et al. 2008; Chan & Carter 2010; 
Weiner, Surana et al. 2010). 14F7, a promising IgG antibody with high binding affinity for 
NeuGc GM3, has a strong anti-tumor effect, comparable to standard chemotherapy 
treatment (Carr et al. 2002).  The mechanism by which it kills the cells is not fully 
elucidated, but no characteristics of apoptosis have been observed; however, membrane 
lesions described as ‘holes’ or ‘pores’ in combination with cellular swelling, often seen in 
oncosis, have been described (Roque-Navarro et al. 2008). We found, when we studied 
the effect of 14F7 treatment on HeLa cells, that 13 proteins had an altered expression 
compared to the non-treated cells. In particular, down-regulated proteins associated with 
the cytoskeleton and their possible functions are discussed in this manuscript. Which 
processes these proteins inhibit or trigger in response to the antibody treatment is yet to 
be verified, but this work significantly advanced our understanding of this novel cell 
death mechanism, which may be followed up by super-resolution microscopy.  
 
 
Manuscript IV 
MS and SPR analysis of the molecular interaction of the unique anti-tumor 
antibody 14F7 with its antigen N-glycolyl GM3 and an anti-idiotypic antibody 
In this manuscript, we investigated the binding interactions between the antibody 14F7 
and its antigen NeuGc GM3 or its anti-idiotypic antibody 4G9. NeuGc GM3 is an 
attractive antigen for cancer immunotherapy as it is tumor-associated, while the highly 
similar NeuAc GM3 is present in almost all healthy tissues. The monoclonal anti-tumor 
antibody 14F7 specifically targets NeuGc GM3 and does not cross-react with the 
abundant NeuAc GM3. 14F7 has remarkable features. For instance, it belongs to the 
IgG class and has a strong binding affinity (within the nanomolar range) to its antigen, 
which is rare for anti-carbohydrate antibodies. Furthermore, it generates an anti-idiotypic 
antibody, 4G9, reported to elicit an efficient anti-anti-idiotypic antibody (Ab3) response 
(Rodriguez et al. 2003). An important aspect in the development of therapeutic 
antibodies is to identify the binding interface between antibody and its antigen or anti-
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idiotypic antibody, and to characterize the molecular recognition mechanism based on 
the structure of the two molecules. For the antibody-antigen interface, a higher affinity or 
extended binding specificity may be engineered, while for the antibody-anti-idiotypic 
antibody interaction, it is possible to partly determine to which Ab2-class (more or less 
promising vaccine candidates) the anti-idiotypic antibody belongs. Since the complexes 
have so far eluded characterization by crystallography, we use (in this manuscript) mass 
spectrometry-based approaches to structurally characterize the interactions of 14F7 with 
antigen or anti-idiotypic antibody. Approaches include SPR, cross-linking and oxidative 
footprinting, a newly developed method to reveal the structure of protein-ligand 
interfaces (Gau et al. 2009), where the accessibility of different parts of the protein is 
probed by oxidation, comparing the free and ligand-bound forms. Mass shifts due to the 
oxidized amino acids can easily be detected by MS. Structural information can thereafter 
be obtaine by comparing the levels of oxidation of the protein alone or in complex with 
the ligand. This method was employed to analyze the binding interface between the 
antibody 14F7 and its ligand NeuGc GM3 (trisaccharide moiety). To investigate the 
binding interactions between 14F7 and the anti-idiotypic antibody 4G9, we applied an 
MS-based cross-linking approach and SPR analysis. The results suggest that not only 
the heavy chain, but also the light chain may be interacting with the ligand NeuGc GM3, 
although additional confirmation is needed. It seems that the binding site of the anti-
idiotypic antibody extends far beyond the ligand binding site, indicating that 4G9 does 
not belong to the most promising anti-idiotype class, Ab2. Interestingly, 4G9 (Fab and 
mAb) strongly affected the kinetics of NeuGc GM3 binding to 14F7, in addition to 
blocking antigen binding. Taken together with the MS results, this indicates that 4G9 
may either induce a long-range conformational change in 14F7 that is transmitted to the 
antigen binding site, or dampen its dynamics. 
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4. Ongoing work and preliminary results 
It is known that gangliosides affect membrane receptor activation, such as EGFR and 
VEGFR (Section 1.1.4). However, membrane protein and lipid studies in biological 
systems are challenging, due to the complexity of cells. To bypass this complexity, a 
unilamellar membrane system consisting of defined lipids and proteins has been used, 
and more studies will most likely follow. The proteoliposomal system has either GM3, 
EGFR or both incorporated in membranes with two different lipid compositions, forming 
uniform liquid-disordered (ld) membrane phases or liquid-disordered/liquid-ordered (ld/lo) 
domains. This difference is important, as the lipid environment (not only the presence of 
gangliosides) has been shown to be important for the activation of the EGFR. Coskun et 
al. showed that NeuAc GM3 inhibits EGFR activation, but only in ld/lo proteoliposomes 
(Coskun et al. 2011). For this reason, we used ld/lo proteoliposomes, and incorporated a 
combination of human EGFR, NeuAc GM3 and NeuGc GM3 (comparing gangliosides 
derived from horse erythrocytes and HeLa cells) into the proteoliposomes. The 
monoclonal antibodies 14F7 mAb (humanized and murine) and P3 mAb (chimera) were 
incubated with the proteoliposomes and the EGFR activation was analyzed using 
Western blotting with phosphotyrosine-specific antibodies. While we could confirm that 
P3 mAb and 14F7 mAb (murine) slightly inhibited EGFR activation at one 
phosphorylation site, a more interesting finding was the presence of EGFR dimers in 
proteoliposomes incubated with these antibodies. Furthermore, we used the sensitive 
method MSD, to measure binding of an anti-NeuGc GM3 antibody (14F7 mAb, 
humanized) and an anti-EGFR antibody (Nimotuzumab) to the proteoliposomes. This 
measurement was repeated twice for anti-NeuGc GM3 and showed that in ld/lo 
proteoliposomes, the presence of both EGFR and NeuGc GM3 ganglioside significantly 
enhances antibody binding. This is true for both anti-EGFR and anti-NeuGc GM3 
antibodies (Figure 6). Apart from the known inhibitory effect of NeuAc GM3 on EGFR 
activation, we observed that P3 and 14F7 (murine) targeting NeuGc GM3 slightly 
decreased activation of EGFR. Moreover, EGF-independent EGFR dimerization was 
observed as a response to the treatment with these antibodies. For the humanized 14F7 
mAb and Nimotuzumab, it was clear that an enhanced binding occurs in the presence of 
both EFGR and NeuGc GM3.  
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Figure 6. Humanized 14F7 (anti-NeuGc GM3) and Nimotuzumab (anti-EGFR) (left column) were 
used to incubate proteoliposomes consisting of a combination of incorporated human EGFR (in 
one case, deglycosylated EGFR) and NeuGc GM3 (derived from horse erythrocytes or HeLa 
cells)(right column). The antibody concentration is showed in the upper row. As seen from the 
values, for both antibody targets (anti-NeuGc GM3 and anti-EGFR), enhanced binding was 
observed when EGFR or NeuGc GM3 was present, respectively.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Proteoliposome 0.1 ug/ml 0.1 ug/ml 1 ug/ml 1 ug/ml 10 ug/ml 10 ug/ml 50 ug/ml 50 ug/ml Antibody 
Ld/lo+NeuGc GM3 
(horse) 263 728 370 239 1122 2273 6749 6366 14F7 
Ld/lo+NeuGc GM3 
(HeLa) 380 361 698 707 3007 2941 10850 4807 14F7 
Ld/lo+EGFR+NeuGc 
GM3 (horse) 16189 16703 16128 13317 17952 14099 22620 24359 14F7 
Ld/lo+EGFR+NeuGc 
GM3 (HeLa) 11399 11178 14982 8842 12593 18420 19782 19787 14F7 
Ld/lo+EGFR 
12211 14356 24400 24937 13620 45752 47567 55913 Nimotuzumab  
Ld/lo+EGFR (degl) 
25284 18792 34340 34939 56822 48558 56919 65584 Nimotuzumab 
Ld/lo+EGFR+NeuGc 
GM3 (horse) 32561 34849 103797 78266 124432 137238 131038 114971 Nimotuzumab 
Ld/lo+EGFR+NeuGc 
GM3 (HeLa) 48540 41883 91197 95867 138545 116754 110370 139031 Nimotuzumab 
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5. Summary and future perspectives 
This thesis focuses on the tumor-associated antigen NeuGc GM3 and its potential for 
cancer immunotherapy. Also discussed are the roles of NeuGc GM3 and hypoxia for 
tumor progression and malignancy. Although many aspects have been studied and a lot 
of data have been gathered, many questions, in particular essential questions regarding 
the mechanism of NeuGc GM3 expression, remain to be answered. How is this antigen, 
despite a deletion in the (human) gene encoding the enzyme necessary for its synthesis, 
is nevertheless expressed in cancer cells? We focused on tumor hypoxia and its 
potential for inducing NeuGc GM3 expression in HeLa cells. SILAC analysis uncovered 
more than 100 proteins with significantly altered expression levels as a response to 
hypoxic conditions, with simultaneously induced NeuGc GM3 expression. Some of these 
proteins were already known hypoxia-induced proteins, such as glycolytic proteins, 
resulting in up-regulated glycolysis. Many other proteins were newly discovered (as 
hypoxic-related proteins), among them clusters of translocases of the inner and outer 
mitochondrial membrane (TIMMs/TOMMs) and mitochondrial ribosomal proteins 
(MPRs). Proteins with a potential to be involved in the mechanism of NeuGc GM3 
expression were also found up-regulated, including succinate dehydrogenase subunit B 
(SDHB), carrying the protein domain deleted in the enzyme required for synthesizing 
NeuGc GM3, and a GM3 ganglioside synthase (ST3GAL5/SLC35E1), catalyzing the 
addition of sialic acid to lactosylceramide. It would be interesting to study these proteins 
further, using gene silencing methods (e.g. siRNA or CRISPR) to investigate whether 
knock-down of these genes affect antigen expression. The SILAC and NeuGc GM3 
expression studies were performed in HeLa cells. As a follow-up study, it would be 
interesting to extend these studies to several other cell lines of different origins. This 
could give a better understanding of tumor-specific response to hypoxia and hypoxia-
induced expression of NeuGc GM3. In addition, alteration of membrane lipids as a 
response to hypoxia is poorly understood, and lipid analyses have been limited to 
detection by specific antibodies. It would be of great interest to investigate another 
unilamellar system developed in Kai Simons laboratory (Coskun & Simons 2010), where 
giant plasma membrane vesicles (GPMVs) (Baumgart et al. 2007) are derived from the 
membrane of cultured cells. This system would allow the analysis of the entire lipid 
 
content of the plasma membrane of cells grown in normoxia or hypoxia, further 
advancing our understanding of tumor hypoxia, an important clinical challenge in the 
treatment of cancer.  
The antibody 14F7, specifically targeting NeuGc GM3, has been important for the work 
discussed in this thesis - from the structural interaction with its antigen or anti-idiotypic 
antibody to investigations of its novel killing mechanism and finally its potential for 
altering EGFR activation. As the two complexes have so far resisted crystallization 
attempts, we employed MS-based approaches to achieve structural information. For the 
interaction between the antibody and the antigen, an approach based on oxidative 
footprinting was used, while for the interaction with the anti-idiotypic antibody, methods 
based on cross-linking mass spectrometry and SPR were employed. These results 
needs confirmation, in particular the cross-linking results. This can be achieved by 
studying the binding of Fab and scFv fragments from the two antibodies. Such fragments 
are currently produced in the lab, in a Master’s project that I have co-supervised, and will 
be tested for binding in the near future. A single-molecule cryo electron microscopy (EM) 
approach (in collaboration with Caroline Jegerschöld at KTH), has also been initiated 
and may be followed up. Even though we are operating at the limits of this technique, we 
hope to gain further insight into how 14F7 binds to its antigen and anti-idiotypic antibody. 
However, as crystal structures of the complexes would provide information at the atomic 
level, this remains the ultimate goal, and crystallization attempts are still ongoing, now 
including the scFvs.   
Finally, we investigated the effect of 14F7 on cancer cells by a SILAC study of HeLa 
cells, targeting the novel cell killing mechanism of 14F7. This work revealed several 
interesting proteins, with the potential of being involved in the formation of “pores” 
observed during the cell treatment process. The most promising proteins will be 
confirmed by Western blotting and is planned to be followed up by the use of super-
resolution microscopy (in collaboration with NorMIC).  
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